Eilean Therapeutics LLC has presented in vivo data for its first-in-class MALT1 degrader, TE-205, as a disease-modifying therapy for ulcerative colitis.
The largest study ever conducted on light therapy for Parkinson’s disease has found that long-term use of Symbyx Biome Pty Ltd.’s non-invasive, at-home photobiomodulation (PBM) devices significantly improved mobility, anxiety, and overall symptom severity.
Interline Therapeutics Inc. has identified new compounds receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).
Proqr Therapeutics NV has received clinical trial application (CTA) authorization under the EMA’s new centralized review process for a phase I study of AX-0810, which is being developed for the treatment of cholestatic diseases such as primary sclerosing cholangitis and biliary atresia.
Nippon Shinyaku Co. Ltd. has divulged quinazoline compounds acting as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors reported to be useful for the treatment of irritable bowel syndrome, psoriasis, arthritis, bacterial infection, systemic lupus erythematosus, pancreatitis, asthma and chronic obstructive pulmonary disease, among others.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized compounds acting as MIR124 activators reported to be useful for the treatment of inflammatory bowel disease and inflammatory disorders.
Esperion Therapeutics Inc. has nominated ESP-2001 as a preclinical development candidate for the treatment of primary sclerosing cholangitis (PSC). The company will now begin IND-enabling studies with the aim of filing an IND application with the FDA to initiate first-in-human studies next year.
Merit Medical Systems Inc. looks to ingest Pentax Medical’s C2 cryoballoon through a $22 million asset purchase expected to close Nov. 1. The C2 treats Barrett’s esophagus, which can be a precursor to esophageal cancer, as well as gastric antral vascular ectasia syndrome. The deal includes a $19 million cash payment at closing and up to $3 million in contingent milestone payments.
NOD2 deficiency is involved in the pathogenesis of Crohn’s disease (CD) due to failure of gut innate immunity and loss of intestinal tissue homeostasis. Orchard Therapeutics Ltd. has presented preclinical data on OTL-104, human hematopoietic stem cell (HSC) gene therapy for the treatment of NOD2-deficient CD.
RSS
